Galectin Change In Cash from 2010 to 2025

GALT Stock  USD 1.59  0.06  3.92%   
Galectin Therapeutics Change In Cash yearly trend continues to be comparatively stable with very little volatility. Change In Cash is likely to outpace its year average in 2025. From the period from 2010 to 2025, Galectin Therapeutics Change In Cash quarterly data regression had mean square error of 236.1 T and mean deviation of  10,493,613. View All Fundamentals
 
Change In Cash  
First Reported
2001-03-31
Previous Quarter
M
Current Value
1.5 M
Quarterly Volatility
6.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46 M, Interest Expense of 3.1 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Galectin Therapeutics over the last few years. It is Galectin Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Very volatile
   Change In Cash   
       Timeline  

Galectin Change In Cash Regression Statistics

Arithmetic Mean2,290,113
Coefficient Of Variation649.05
Mean Deviation10,493,613
Median2,967,000
Standard Deviation14,864,085
Sample Variance220.9T
Range60.3M
R-Value0.05
Mean Square Error236.1T
R-Squared0
Significance0.85
Slope158,633
Total Sum of Squares3314.1T

Galectin Change In Cash History

20258.5 M
20248.1 M
20237.1 M
2022-21.1 M
202112.5 M
2020-20.3 M
201939.2 M

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as Change In Cash, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash8.1 M8.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.